期刊文献+

二甲双胍联合阿卡波糖对2型糖尿病降糖作用的临床疗效评价 被引量:4

Blood Glucose Reduction by Metformin plus Acarbose:Evaluation of the Clinical Affects and Curative Effects in Treating Type 2 Diabetes Mellitus
原文传递
导出
摘要 目的观察单用二甲双胍与二甲双胍联合阿卡波糖对2型糖尿病(type 2diabetes mellitus,T2DM)降糖作用的临床疗效。方法对2010年1~10月就诊有典型易饥多食的T2DM患者45例,随机分为二甲双胍组20例和二甲双胍联合阿卡波糖25例,疗程12周。结果二甲双胍组与二甲双胍联合阿卡波糖组治疗后对患者的饥饿感和食量改善差异有统计学意义(P<0.05),空腹及餐后血糖差异(P<0.01)、空腹血糖达标比例差异(P<0.01)、餐后血糖达标比例差异(P<0.05)均有统计学意义。结论二甲双胍联合阿卡波糖能显著改善T2DM患者的食欲及食量,从而明显降低空腹及餐后血糖。 Objective To observe and compare the clinical affects and curative effects between using metformin and metformin plus acarbose in the treatment of type 2 diabetes mellitus(T2DM).Methods From January to October 2010,45 T2DM patients with common symptoms of easy-starving and overeating were randomized into two groups and treated for 12 weeks with either metformin(n=20) or metformin plus acarbose(n=25).Results After the treatment,significant differences were found between the two groups in the improvement on patients' sense of starving and quantity of eating(P0.05),fasting and postprandial blood glucose(P0.01),up-to-standard rate of fasting blood glucose(P0.01),and up-to-standard rate of postprandial blood glucose(P0.05).Conclusion The combination of metformin and acarbose can substantially improve the appetite and quantity of eating for patients with T2DM,hence significant reductions of fasting and postprandial blood glucose level can be feasibly achieved.
作者 吴晓梅
出处 《华西医学》 CAS 2011年第6期832-834,共3页 West China Medical Journal
关键词 2型糖尿病 二甲双胍 阿卡波糖 食欲与食量 血糖 Type 2 diabetes mellitus Metformin Acarbose Appetite and quantity of eating Blood glucose
  • 相关文献

参考文献7

二级参考文献13

  • 1池芝盛.拜糖平(Glucobay)的临床应用[J].中国糖尿病杂志,1995,3(3):165-168. 被引量:49
  • 2徐爱平.拜糖平与胰岛素联合应用治疗糖尿病56例[J].实用中西医结合临床,2006,6(4):58-58. 被引量:1
  • 3Gaede P, Lund-Andersen H, Parving HH, et al. Effect of a multifactorial intervention on mortality in type 2 Diabetes. N Engl J Med, 2008, 358: 580-591.
  • 4Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med, 2008, 359 : 1577-1589.
  • 5Gaede P, Vedel P, Larsen N, et al. Muhifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med, 2003, 348: 383-393.
  • 6Djaberi R, Beishuizen ED, Pereira AM, et al. Non-invasive cardiac imaging teehniques and vascular tools for the assessment of cardiovascular disease in type 2 diabetes mellitus. Diabetologis,2008, 51 : 1581-1593.
  • 7Lund SS, Tarnow L, Stehouwer CD, et al. Impact of metformin versus repaglinide on non-glycaemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes. Eur J Endocrinol, 2008, 158 : 631- 641.
  • 8Scarpello JH, Howlett HC. Metformin therapy and clinical uses. Diab Vasc Dis Res, 2008, 5: 157-167.
  • 9Holman R. Metfomin as first choice in oral diabetes treatment: the UKPDS experience. Journ Annu Diabetol Hotel Dieu, 2007,13 : 13 -20.
  • 10Manuel LR, Covadonga MA, Francisco AB, et al. Effects of metformin versus ethinyl-estradiol plus cyproterone acetate on ambulatory blood pressure monitoring and carotid intima media thickness in women with the polycystic ovary syndrome. Fertil Steri, 2009, 91:2527-2536.

共引文献104

同被引文献25

引证文献4

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部